[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368318-105":59,"doc-detail-368318-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","extensive-review-of-nanomedicine-strategies-targeting-the-tumor-microenvironment-in-pdac","Extensive Review of Nanomedicine Strategies Targeting the Tumor Microenvironment in PDAC","","Pancreatic ductal adenocarcinoma (PDAC) remains highly lethal due to its dense proconnective matrix and immunosuppressive tumor microenvironment (TME) that drive progression, metastasis, and poor drug access. The extracellular matrix collapses vasculature, elevates interstitial fluid pressure, and blocks lymphatic return, limiting penetration and immune infiltration. Reshaping the TME and improving perfusion, deep delivery, and immune restoration are key strategies. Nanotechnology-based nanoscale drug delivery systems (NDDSs) can enhance stability, penetration, and reduce systemic toxicity, yet face barriers in targeting, release control, immunogenicity, and scalable cost-effective manufacturing. This review surveys recent nanomedicine approaches for overcoming resistance in PDAC.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/extensive-review-of-nanomedicine-strategies-targeting-the-tumor-microenvironment-in-pdac/368318/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/extensive-review-of-nanomedicine-strategies-targeting-the-tumor-microenvironment-in-pdac/368318.png","ImageObject",300,407,{"name":92,"@type":93},"Miles","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-11","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is the tumor microenvironment in PDAC a major barrier to treatment?","Question",{"text":113,"@type":114},"PDAC’s proconnective matrix and immunosuppressive TME promote tumor progression and metastasis while impairing drug delivery. Extracellular matrix–driven vascular collapse, increased interstitial fluid pressure, and obstructed lymphatic return hinder penetration and immune cell infiltration.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What advantages do nanoscale drug delivery systems offer in PDAC therapy?",{"text":118,"@type":114},"Nanoscale drug delivery systems can improve in vivo drug stability, enhance tumor penetration, and reduce systemic toxicity. These properties support more effective delivery within the hostile PDAC microenvironment.",{"name":120,"@type":111,"acceptedAnswer":121},"What challenges limit clinical translation of nanotechnology for PDAC?",{"text":122,"@type":114},"Clinical translation requires precise targeting and controlled drug release. Potential immune responses to nanocarriers, along with scalability and cost-effectiveness of production, also pose major hurdles.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},368318,1790197407,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","International Journal of Nanomedicine  \n Open Access Full Text Article  \nREVIEW  \nExtensive Review of Nanomedicine Strategies Targeting the Tumor Microenvironment in PDAC  \nXing Liu 1 , Yidan Shao2 , Yunjiang Li 3 , Zuhua Chen 3 , Tingting Shi2 , Qiao Tong2 , Xi Zou 2 , Liping Ju2 , Jinming Pan2 , Rangxiao Zhuang2 , *, Xuwang Pan 2 , *  \n1School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 311400, People’s Republic of China; 2Department of Pharmaceutical Preparation, Affiliated Hangzhou Xixi Hospital, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310023, People’s Republic of China; 3Radiology Department, Affiliated Hangzhou Xixi Hospital, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310023, People’s Republic of China  \n*These authors contributed equally to this work  \nCorrespondence: Rangxiao Zhuang; Xuwang Pan, Department of Pharmaceutical Preparation, Affiliated Hangzhou Xixi Hospital, Zhejiang Chinese Medical University, 2, Hengbu Road, Hangzhou, Zhejiang, 310023, People’s Republic of China, Tel +86-571-8648-1609, [Email zhuangrangxiao@sina.com](Email zhuangrangxiao@sina.com); [pxuwang@163.com](pxuwang@163.com)  \n\n| Abstract: Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers in the world, mainly because of its powerful proconnective tissue proliferation matrix and immunosuppressive tumor microenvironment (TME), which promote tumor progression and metastasis. In addition, the extracellular matrix leads to vascular collapse, increased interstitial fluid pressure, and obstruction of lymphatic return, thereby hindering effective drug delivery, deep penetration, and immune cell infiltration. Therefore, reshaping the TME to enhance tumor perfusion, increase deep drug penetration, and reverse immune suppression has become a key therapeutic strategy. Traditional therapies for PDAC, including surgery, radiation, and chemotherapy, face significant limitations. Surgery is challenging due to tumor location and growth, while chemotherapy and radiation are hindered by the dense extracellular matrix and immunosuppressive TME. In recent years, the advancement of nanotechnology has provided new opportunities to improve drug efficacy. Nanoscale drug delivery systems (NDDSs) provide several advantages, including improved drug stability in vivo, enhanced tumor penetration, and reduced systemic toxicity. However, the clinical translation of nanotechnology in PDAC therapy faces several challenges. These include the need for precise targeting and control over drug release, potential immune responses to the nanocarriers, and the scalability and cost-effectiveness of production. This article provides an overview of the latest nanobased methods for achieving better therapeutic outcomes and overcoming drug resistance. We pay special attention to TME-targeted therapy in the context of PDAC, discuss the advantages and limitations of current strategies, and emphasize promising new developments. By emphasizing the enormous potential of NDDSs in improving the treatment outcomes of patients with PDAC, while critically discussing the limitations of traditional therapies and the challenges faced by nanotechnology in achieving clinical breakthroughs, our review paves the way for future research in this rapidly developing field.\u003Cbr>Keywords: nanoscale, drug delivery systems, pancreatic ductal adenocarcinoma, tumor microenvironment, deep penetration |\n| --- |\n| Introduction\u003Cbr>Pancreatic ductal adenocarcinoma (PDAC) is a malignancy with a notably high mortality rate, with increasing incidence and mortality rates on a global scale. In the United States, the incidence rates of PDAC increased annually by 0.6% to 1% between 2015 and 2019.1 Projections for 2024 anticipate the diagnosis of approximately 66,440 new cases in the United States, with an estimated 51,750 resultant fatalities.1 According to the GLOBOCAN 2022 statistics, among all malignant tumors worldwide, there were 510,","cbCaipEOFJu0PDCb","https://ap.wps.com/l/cbCaipEOFJu0PDCb","pdf",17394575,28,"English","# Abstract\n# Introduction","[{\"question\":\"Why is the tumor microenvironment in PDAC a major barrier to treatment?\",\"answer\":\"PDAC’s proconnective matrix and immunosuppressive TME promote tumor progression and metastasis while impairing drug delivery. Extracellular matrix–driven vascular collapse, increased interstitial fluid pressure, and obstructed lymphatic return hinder penetration and immune cell infiltration.\"},{\"question\":\"What advantages do nanoscale drug delivery systems offer in PDAC therapy?\",\"answer\":\"Nanoscale drug delivery systems can improve in vivo drug stability, enhance tumor penetration, and reduce systemic toxicity. These properties support more effective delivery within the hostile PDAC microenvironment.\"},{\"question\":\"What challenges limit clinical translation of nanotechnology for PDAC?\",\"answer\":\"Clinical translation requires precise targeting and controlled drug release. Potential immune responses to nanocarriers, along with scalability and cost-effectiveness of production, also pose major hurdles.\"}]","Extensive Review of Nanomedicine Strategies Targeting the Tumor Microenvironment in PDAC | PDF",1790176271,71,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0a308b62ea43fc28fdc39d2b0071d4e4.webp",983,1272,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b573145747f2f4acd8b08460d3a41713.webp",982,1270,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/33b30ab0e0acb4eafd72c779c10b14e1.webp",981,1269,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/29ef210120eee3725c4032edcf24e7b7.webp",980,1268]